Placebo or active control trials of antipsychotic drugs?

Archives of General Psychiatry

Volumn 60, Issue 5, 2003, Pages 458-464

  Fleischhacker, W Wolfgang ^a   Czobor, Pal ^c   Hummer, Martina ^a   Kemmler, Georg ^b   Kohnen, Ralf ^a   Volavka, Jan ^c  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c Inst Med Res Mgmt and Biometr   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ETHICS; HUMAN; META ANALYSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; ETHICS, CLINICAL; HUMANS; MATHEMATICS; META-ANALYSIS; PATIENT SELECTION; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SAMPLE SIZE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0037967387     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.5.458     Document Type: Review

References (39)

1. Carpenter WT, Conley RR. Sense and nonsense: an essay on schizophrenia research ethics. Schizophr Res. 1999;35:219-225.
2. Carpenter WT Jr, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 1997;54: 401-407.
3. Fleischhacker WW, Hummer M, Kemmler G, Volavka J, for the European Foundation for Research on Schizophrenia. Placebo-controlled trials in patients suffering from schizophrenia: feasibility, ethical and methodological considerations [abstract]. Schizophr Res. 2001;49(suppl):227-228.
4. Volavka J. Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Arch Gen Psychiatry. 1998;55:280-281, 283.
5. Zipursky RB, Darby P. Placebo-controlled studies in schizophrenia - ethical and scientific perspectives: an overview of conference proceedings. Schizophr Res. 1999;35:189-200.
6. International Conference on Harmonisation Steering Committee. Note for Guidance on Choice of Control Group in Clinical Trials. London, England: International Conference of Harmonization; July 2000. ICH Topic E10 (CPMO/ICH/364/96).
7. Aras G. Superiority, noninferiority, equivalence, and bioequivalence - revisited. Drug Information J. 2001;35:1157-1164.
8. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
9. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 2: practical issues and specific cases. Ann Intern Med. 2000;133:464-470.
10. Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med. 2000;133:474-475.
11. Emanuel EJ, Miller FG. The ethics of placebocontrolled trials - a middle ground. N Engl J Med. 2001;345:915-919.
12. Leber PD. Hazards of inference: the active control investigation. Epilepsia. 1989;30(suppl 1): S57-S63.
13. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics. 1999;55:484-487.
14. Woods SW, Stolar M, Sernyak MJ, Charney DS. Consistency of atypical antipsychotic superiority to placebo in recent clinical trials. Biol Psychiatry. 2001;49:64-70.
15. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
16. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ. 2000;321:1371-1376.
17. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry. 2001; 158:1449-1454.
18. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20:699-702.
19. Robinson D, Woerner MG, Pollack S, Lerner G. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol. 1996;16:170-176.
20. Mohr P, Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. J Clin Psychopharmacol. 2000;20:240-245.
21. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155: 230-233.
22. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-835.
23. Margraf J, Ehlers A, Roth WT, Clark DB, Sheikh J, Agras WS, Taylor CB. How"blind" are double-blind studies? J Consult Clin Psychol. 1991;59:184-187.
24. Hummer M, Kemmler G, Eder U, Hofer A, Oehl M, Weiss E, Holzmeister R, Fleischhacker WW. Placebo-controlled clinical trials: patients' attitudes. J Clin Psychiatry. In press.
25. Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry. 2002;159:573-584.
26. Fleischhacker WW, Burns T, for the European Group for Research in Schizophrenia. Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology (Berl). 2002;162:82-84.
27. Edinburgh 2000: Declaration of Helsinki. Available at: http://www.wma.net. Accessed July 2002.
28. Curson DA, Hirsch SR, Platt SD, Bamber RW, Barnes T. Does short term placebo treatment of chronic schizophrenia produce long term harm? BMJ. 1986;293:726-728.
29. Wyatt RJ, Henter ID, Bartko JJ. The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999;46:1092-1105.
30. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
31. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS). In: American Psychiatric Association, ed. Handbook of Psychiatric Measures. Washington, DC: Amercian Psychiatric Association; 2000:494-497.
32. Guy W. Clinical Global Impressions Scale. In: Amercian Psychiatric Association, ed. Handbook of Psychiatric Measures. Washington, DC: Amercian Psychiatric Association; 2000:100-102.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Assoc Inc; 1988.
34. O'Brien RG. A tour of UnifyPow: a SAS Module/Macro for sample-size analysis. In: Proceedings of the 23rd Annual Users Group International Conference; March 22-25, 1998; Nashville, Tenn. Cary, NC: SAS Institute; 1998:1346-1355.
35. International Conference on Harmonisation Steering Committee. Note for Guidance on Statistical Principles in Clinical Trials. London, England: International Conference of Harmonization; March 1998. ICH Topic E9 (CPMP/ICH/363/96).
36. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990;9:65-71.
37. Zucker DM, Wittes JT, Schabenberger O, Brittain E. Internal pilot studies, II: comparison of various procedures. Stat Med. 1999;18:3493-3509.
38. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-190.
39. Butler A, Wighton A, Welch CP, Tweed JA, Byrom BD, Reynolds C. The efficacy of zotepine in schizophrenia: a meta-analysis of BPRS and improvement scale scores. Int J Psychiatry Clin Pract. 2000;4:19-27.